Orforglipron vs Tirzepatide
Extensively Studied vs FDA Approved
avoid Researched · 95% Dual GIP/GLP-1 agonist overlaps with GLP-1 mechanism; combination contraindicated.
Molecular Data
Orforglipron Tirzepatide
Weight 882.974 Da 4,813.55 Da
Half-life 25-68 hours ~5 days (120 hours)
Chain Non-peptide small molecule 39 amino acids
Type Small-molecule GLP-1R agonist Dual GLP-1/GIP agonist
Key Benefits
Orforglipron
01 Significant weight loss (up to 12.4% at 72 weeks)
02 Robust diabetes control (HbA1c reduction 1.3-1.6%)
03 Once-daily oral tablet format
04 No refrigeration or food restrictions required
05 Reduced cardiovascular risk markers
Tirzepatide
01 Dramatic weight loss (15-22% body weight)
02 Superior diabetes control
03 Reduced cardiovascular risk (26% reduction in MACE)
04 Improved insulin sensitivity
05 Appetite suppression
06 Preserved muscle mass with exercise
Dosing Protocols
Orforglipron
Start 3-6mg daily, titrate up to 12-36mg based on response / Once daily oral tablet
Tirzepatide
2.5mg starting, titrate up to 5-15mg weekly / Once weekly (same day each week)
Weight loss initiation 2.5mg Once weekly x 4 weeks
Weight loss progression 5mg Once weekly
Weight loss optimization 7.5-10mg Once weekly
Maximum weight loss 12.5-15mg Once weekly
Diabetes management (mild) 5-7.5mg Once weekly
Diabetes management (severe) 10-15mg Once weekly
Side Effects
Orforglipron
Diarrhea (more prevalent than with injectable GLP-1s)
Nausea (typically improves after first month)
Appetite reduction
Tirzepatide
Nausea (mild to moderate, first 2-4 weeks)
Appetite reduction
Possible fatigue during adaptation
Diarrhea or constipation
Reduced food cravings
Contraindications
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy and breastfeeding
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Orforglipron Tirzepatide
Status Extensively Studied FDA Approved
References 4 studies 8 studies
Latest — 2025-12
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.